argenx’s (ARGX) “Outperform” Rating Reiterated at Oppenheimer

Oppenheimer reiterated their outperform rating on shares of argenx (NASDAQ:ARGX) in a report published on Thursday,Benzinga reports. They currently have a $675.00 price target on the stock, up from their prior price target of $646.00.

A number of other research analysts have also recently issued reports on ARGX. William Blair upgraded argenx from a “market perform” rating to an “outperform” rating in a research note on Friday, November 1st. Wolfe Research upgraded shares of argenx from a “peer perform” rating to an “outperform” rating and set a $697.00 price target on the stock in a research note on Tuesday, November 12th. Baird R W lowered shares of argenx from a “strong-buy” rating to a “hold” rating in a research note on Friday, November 1st. Guggenheim lifted their target price on shares of argenx from $585.00 to $665.00 and gave the stock a “buy” rating in a report on Friday, November 1st. Finally, Scotiabank upgraded shares of argenx from a “sector perform” rating to a “sector outperform” rating and increased their price target for the company from $439.00 to $715.00 in a report on Tuesday, November 5th. Three research analysts have rated the stock with a hold rating, nineteen have assigned a buy rating and one has given a strong buy rating to the stock. According to MarketBeat, the stock presently has an average rating of “Moderate Buy” and a consensus target price of $630.42.

argenx Trading Up 1.5 %

Shares of argenx stock opened at $605.92 on Thursday. argenx has a 12 month low of $327.73 and a 12 month high of $611.22. The firm has a market capitalization of $36.23 billion, a P/E ratio of -688.55 and a beta of 0.61. The business has a fifty day simple moving average of $557.73 and a two-hundred day simple moving average of $488.21.

argenx (NASDAQ:ARGX) last posted its quarterly earnings data on Thursday, October 31st. The company reported $1.39 EPS for the quarter, topping the consensus estimate of $0.10 by $1.29. argenx had a negative net margin of 2.11% and a negative return on equity of 1.45%. The business had revenue of $588.88 million for the quarter, compared to analyst estimates of $543.29 million. During the same quarter in the previous year, the firm posted ($1.25) earnings per share. Analysts predict that argenx will post 2.2 earnings per share for the current year.

Institutional Trading of argenx

A number of hedge funds and other institutional investors have recently added to or reduced their stakes in the business. J.Safra Asset Management Corp boosted its stake in shares of argenx by 590.0% during the 2nd quarter. J.Safra Asset Management Corp now owns 69 shares of the company’s stock worth $30,000 after acquiring an additional 59 shares during the last quarter. Blue Trust Inc. raised its holdings in argenx by 620.0% in the 2nd quarter. Blue Trust Inc. now owns 72 shares of the company’s stock worth $28,000 after purchasing an additional 62 shares during the period. GAMMA Investing LLC lifted its position in argenx by 51.3% during the second quarter. GAMMA Investing LLC now owns 118 shares of the company’s stock valued at $51,000 after purchasing an additional 40 shares in the last quarter. Cromwell Holdings LLC grew its holdings in argenx by 73.3% during the third quarter. Cromwell Holdings LLC now owns 156 shares of the company’s stock valued at $85,000 after purchasing an additional 66 shares during the period. Finally, Point72 Hong Kong Ltd purchased a new stake in argenx in the second quarter worth about $76,000. 60.32% of the stock is owned by hedge funds and other institutional investors.

About argenx

argenx SE, a biotechnology company, engages in the developing of various therapies for the treatment of autoimmune diseases in the United States, Japan, Europe, Middle East, Africa, and China. Its lead product candidate is efgartigimod for the treatment of patients with myasthenia gravis, immune thrombocytopenia, pemphigus vulgaris, generalized myasthenia gravis, chronic inflammatory demyelinating polyneuropathy, thyroid eye disease, bullous pemphigoid, myositis, primary sjögren’s syndrome, post-covid postural orthostatic tachycardia syndrome, membranous nephropathy, lupus nephropathy, anca-associated vasculitis, and antibody mediated rejection; ENHANZE SC; Empasiprubart for multifocal motor neuropath, delayed graft function, and dermatomyositis; and ARGX-119 for congenital myasthenic syndrome and amyotrophic lateral sclerosis.